Farmacie pro praxi. 2023;19(1):11-14 | DOI: 10.36290/lek.2023.001

Anastrozole - off­‑label use in men

Miroslav Turjap1, Roman Král2, Jan Juřica3, 4
1 Lékárna FN Ostrava
2 Urologická klinika, FN Ostrava
3 Masarykova univerzita, Farmakologický ústav, Lékařská fakulta a Ústav farmakologie a toxikologie, Farmaceutická fakulta, Brno
4 Ústavní lékárna, Masarykův onkologický ústav, Brno

Anastrozole is a highly selective nonsteroidal aromatase inhibitor. It is approved for the treatment of hormone receptor-positive breast cancer in postmenopausal women. Nonetheless, aromatase inhibitors have also been used off-label for many years in men. This article outlines empirical non-oncological anastrozole uses in men and briefly presents some current clinical trials involving the male population.

Keywords: anastrozole, aromatase inhibitors, men, off­‑label use, clinical trials.

Accepted: February 17, 2023; Published: March 3, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Turjap M, Král R, Juřica J. Anastrozole - off­‑label use in men. Pharmacy for Practice. 2023;19(1):11-14. doi: 10.36290/lek.2023.001.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. SPC Arimidex [Internet]. Available from: www.sukl.cz/modules/medication/search.php. (přístup 25. 11. 2022)
    2. AISLP (verze pro PC). build 2022. 4. INPHARMEX, spol. s r. o., Praha.
    3. Česká onkologická společnost. Modrá kniha České onkologické společnosti, 28. aktualizace (3/2022). Masarykův onkologický ústav, Brno 2022.
    4. Anastrozole. In: Lexi­‑Drugs Multinational [Mobile app, build 7. 5. 4, subscription needed]. Hudson (OH): Lexicomp Inc.
    5. Mauras N, Bishop K, Merinbaum D, et al. Pharmacokinetics and pharmacodynamics of anastrozole in pubertal boys with recent­‑onset gynecomastia. The Journal of clinical endocrinology and metabolism. 2009;94(8):2975-8. Go to original source...
    6. Tan RB, Guay AT, Hellstrom WJ. Clinical use of aromatase inhibitors in adult males. Sexual Medicine Reviews. 2014;2(2):79-90. Go to original source... Go to PubMed...
    7. Finkelstein JS, Lee H, Burnett­‑Bowie SA, et al. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med. 2013;369(11):1011-22. Go to original source...
    8. Rotstein A. Sex hormone synthesis, regulation, and function. McMaster Pathophysiology Review [Internet]. dostupné z www.pathophys.org/sexhormones/#Sex_hormone_effects. (přístup 25. 11. 2022). Go to original source...
    9. Wit JM, Hero M, Nunez SB. Aromatase inhibitors in pediatrics. Nature reviews Endocrinology. 2011;8(3):135-47. Go to original source... Go to PubMed...
    10. Salonia A, Bettocchi C, Carvalho J. EAU Guidelines on Sexual and Reproductive Health - Limited Update 2022 [Internet]. Dostupné z: https://uroweb.org/guidelines/sexual­‑and­‑reproductive­‑health. (přístup 25. 11. 2022).
    11. Schulster M, Bernie AM, Ramasamy R. The role of estradiol in male reproductive function. Asian J Androl. 2016;18(3):435-40. Go to original source...
    12. Ring JD, Lwin AA, Kohler TS. Current medical management of endocrine­‑related male infertility. Asian J Androl. 2016;18(3):357-63. Go to original source...
    13. Shah T, Nyirenda T, Shin D. Efficacy of anastrozole in the treatment of hypogonadal, subfertile men with body mass index ≥25 kg/m2. Translational Andrology and Urology. 2021;10(3):1222-8. Go to original source... Go to PubMed...
    14. Ramasamy R, Scovell JM, Kovac JR, et al. Elevated serum estradiol is associated with higher libido in men on testosterone supplementation therapy. Eur Urol. 2014;65(6):1224-5. Go to original source... Go to PubMed...
    15. Schlegel PN. Aromatase inhibitors for male infertility. Fertility and sterility. 2012;98(6):1359-62. Go to original source... Go to PubMed...
    16. Simonneau G, Montani D, Celermajer DS, at al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. European Respiratory Journal. 2019;53(1):1801913. Go to original source...
    17. Rodriguez­‑Arias JJ, Garcia­‑Alvarez A. Sex Differences in Pulmonary Hypertension. Front Aging. 2021;2:727558. Go to original source...
    18. Tofovic SP, Jackson EK. Estradiol Metabolism: Crossroads in Pulmonary Arterial Hypertension. International Journal of Molecular Sciences. 2020;21(1):116. Go to original source...
    19. Kawut SM, Archer­‑Chicko CL, DeMichele A, et al. Anastrozole in Pulmonary Arterial Hypertension. A Randomized, Double­‑Blind, Placebo­‑controlled Trial. American journal of respiratory and critical care medicine. 2017;195(3):360-8. Go to original source...
    20. ClinicalTrials.gov Identifier: NCT03229499. Pulmonary Hypertension and Anastrozole Trial (PHANTOM) [Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT03229499 (přístup 25. 11. 2022).
    21. Colleluori G, Chen R, Turin CG, et al. Aromatase Inhibitors Plus Weight Loss Improves the Hormonal Profile of Obese Hypogonadal Men Without Causing Major Side Effects. Frontiers in endocrinology. 2020;11:277. Go to original source...
    22. ClinicalTrials.gov Identifier: NCT03490513. Aromatase Inhibitors and Weight Loss in Severely Obese Men With Hypogonadism [Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT03490513 (přístup 25. 11. 2022).
    23. Dias JP, Melvin D, Shardell M, et al. Effects of Transdermal Testosterone Gel or an Aromatase Inhibitor on Prostate Volume in Older Men. The Journal of clinical endocrinology and metabolism. 2016;101(4):1865-71. Go to original source...
    24. Dias JP, Melvin D, Simonsick EM, et al. Effects of aromatase inhibition vs. testosterone in older men with low testosterone: randomized­‑controlled trial. Andrology. 2016;4(1):33-40. Go to original source... Go to PubMed...
    25. Dias JP, Shardell MD, Carlson OD, et al. Testosterone vs. aromatase inhibitor in older men with low testosterone: effects on cardiometabolic parameters. Andrology. 2017;5(1):3-0. Go to original source...
    26. Helo S, Ellen J, Mechlin C, et al. A Randomized Prospective Double-Blind Comparison Trial of Clomiphene Citrate and Anastrozole in Raising Testosterone in Hypogonadal Infertile Men. The Journal of Sexual Medicine. 2015;12(8):1761-9. Go to original source... Go to PubMed...
    27. ClinicalTrials.gov Identifier: NCT03933618. Anastrazole and Clomiphene to Evaluate Hypogonadal Symptoms and Erectile Function (CAP) [Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT03933618 (přístup 25. 11. 2022).
    28. Neely EK, Kumar RB, Payne SL, et al. Letrozole vs anastrozole for height augmentation in short pubertal males: first year data. The Journal of clinical endocrinology and metabolism. 2014;99(11):4086-93. Go to original source...
    29. Mauras N, Ross JL, Gagliardi P, et al. Randomized Trial of Aromatase Inhibitors, Growth Hormone, or Combination in Pubertal Boys with Idiopathic, Short Stature. The Journal of clinical endocrinology and metabolism. 2016;101(12):4984-93. Go to original source...
    30. Miller BS, Ross J, Ostrow V. Height outcomes in children with growth hormone deficiency and idiopathic short stature treated concomitantly with growth hormone and aromatase inhibitor therapy: data from the ANSWER program. International Journal of Pediatric Endocrinology. 2020; (19) 2020. Go to original source...
    31. Reiter EO, Mauras N, McCormick K, et al. Bicalutamide plus anastrozole for the treatment of gonadotropin­‑independent precocious puberty in boys with testotoxicosis: a phase II, open­‑label pilot study (BATT). J Pediatr Endocrinol Metab. 2010;23(10):999-1009. Go to original source...
    32. Snyder PJ. Use of androgens and other hormones by athletes. In: Matsumoto A, Fricker P, editors. UpToDate [Internet]. Waltham, MA: UpToDate; 2022 (přístup 25. 11. 2022; Subscription needed).
    33. The World Anti­‑Doping Agency (WADA). World Anti­‑Doping Program - Prohibited List [Internet]. Dostupné z: https://www.wada­‑ama.org/en/prohibited­‑list (přístup 25. 11. 2022).

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.